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HIV protease inhibitor (PI) therapy results in the rapid selection of drug resistant viral variants
harbouring one or two substitutions in the viral protease. To combat PI resistance
development, two approaches have been developed. The first is to increase the level of PI
in the plasma of the patient, and the second is to develop novel PI with high potency against
the known PI-resistant HIV protease variants. Both approaches share the requirement for a
considerable increase in the number of protease mutations to lead to clinical resistance,
thereby increasing the genetic barrier. We investigated whether HIV could yet again find a way
to become less susceptible to these novel inhibitors.
Methods and Findings
We have performed in vitro selection experiments using a novel PI with an increased genetic
barrier (RO033-4649) and demonstrated selection of three viruses 4- to 8-fold resistant to all PI
compared to wild type. These PI-resistant viruses did not have a single substitution in the viral
protease. Full genomic sequencing revealed the presence of NC/p1 cleavage site substitutions
in the viral Gag polyprotein (K436E and/or I437T/V) in all three resistant viruses. These changes,
when introduced in a reference strain, conferred PI resistance. The mechanism leading to PI
resistance is enhancement of the processing efficiency of the altered substrate by wild-type
protease. Analysis of genotypic and phenotypic resistance profiles of 28,000 clinical isolates
demonstrated the presence of these NC/p1 cleavage site mutations in some clinical samples
(codon 431 substitutions in 13%, codon 436 substitutions in 8%, and codon 437 substitutions in
10%). Moreover, these cleavage site substitutions were highly significantly associated with
reduced susceptibility to PI in clinical isolates lacking primary protease mutations. Furthermore,
we used data from a clinical trial (NARVAL, ANRS 088) to demonstrate that these NC/p1
cleavage site changes are associated with virological failure during PI therapy.
Conclusions
HIV can use an alternative mechanism to become resistant to PI by changing the substrate
instead of the protease. Further studies are required to determine to what extent cleavage site
mutations may explain virological failure during PI therapy.
The Editors’ Summary of this article follows the references.
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Selection of drug-resistant viruses is a major problem
causing therapy failure in a substantial proportion of patients
infected with HIV-1. Increasingly, these drug-resistant viruses
are transmitted and reported to persist in the absence of
therapy [1–4]. Moreover, the use of sequential monotherapy
in developed countries has led to the emergence of HIV
variants that are resistant to one or more classes of antivirals.
The introduction of protease inhibitors (PIs) has been one
of the key components in the success of combination therapy.
The viral protease is required for the cleavage of the precursor
Gag and GagPol polyproteins, resulting in mature infectious
virus particles. The genetic basis of resistance to PIs has been
well documented in the last decade. The development of PI
resistance is usually a stepwise process [5–7]. A change in the
substrate-binding pocket of protease is thought to be the ﬁrst
step, leading to decreased binding of the inhibitor (and hence
to resistance), as well as decreased binding of the natural
substrate and thus affecting virus replication [8–11]. To
compensate for this, additional mutations accumulate within
the protease sequence that have minor effects on resistance,
but improve the processing efﬁciency of the resistant enzyme,
thus restoring (at least partially) viral replication [11–14].
Besides the genetic alterations in the protease sequence,
compensatory mutations have been described in the viral Gag
polyprotein, most commonly found in the vicinity of the
actual cleavage sites. The mutations are thought to adapt the
virus to the altered substrate-binding cleft of the mutant
enzyme [14–18]. Therefore, substrate alterations are generally
believed to be compensatory changes that do not directly
affect protease resistance.
Two approaches have been developed to prevent PI
resistance. The ﬁrst approach is to increase the level of PI
in the plasma of the patient by combining them with low-dose
ritonavir, a cytochrome P450 3A4 enzyme inhibitor [19]. As a
consequence of this, drug levels are higher and the virus
needs to acquire more mutations in the protease sequence to
achieve clinical resistance. The second approach is to develop
novel HIV PIs with high potency against known PI-resistant
HIV variants [20–22]. Both approaches require a considerable
increase in the number of protease mutations necessary to
achieve clinical resistance, thereby increasing the genetic
barrier.
It should not come as a surprise that HIV would use
alternative resistance mechanisms that could defeat the
strategy of imposing a high genetic barrier. Indeed, a clinical
trial using the potent PI lopinavir boosted with ritonavir in
therapy-naive patients, and thus exploiting a high genetic
barrier approach, revealed virological failure in 20% of
patients [23]. In this study, failure could not be attributed to
the development of traditional protease resistance mutations,
as none of the viruses obtained from patients failing treat-
ment displayed changes in the viral protease sequence, thus
suggesting a novel resistance mechanism. We have performed
clinical and laboratory studies to test whether HIV can indeed
become resistant to PI without changing the viral protease.
Methods
Viral Culture
Cells. SupT1 and MT-2 cells were maintained in RPMI 1640
medium with L-glutamine (BioWhittaker, http://www.
cambrex.com) supplemented with 10% fetal bovine serum
(FBS; Gibco, http://www.invitrogen.com) and 10 lg/ml genta-
micine (Gibco). 293T cells were maintained in Dulbecco
modiﬁed Eagle medium (BioWhittaker) supplemented with
10% FBS and 10 lg/ml gentamicin. All cells were passaged
twice weekly.
In vitro selection experiments. Multiple in vitro selection
experiments were performed using the HIV-1 reference
strain HXB2 in the presence of increasing concentrations
of RO033-4649 or ritonavir. The selection was initiated by
infection of SupT1 cells (MOI 0.01) in the absence of drug.
After a 1-h incubation at 37 8C, culture medium supple-
mented with the drug was added to a ﬁnal volume of 10 ml.
During the experiment the culture was monitored daily for
the appearance of syncytia. When full-blown syncytia were
observed, cell-free virus was used to initiate the next cell
culture passage. The RO033-4649 concentration was raised
during the subsequent passages from 20 nM (IC50 of HXB2) to
100 nM (IVS-32) and 120 nM (IVS-1 and IVS34; passage 1: 20
nM; passage 2: 40 nM; passage 3: 60 nM; passages 4 and 5: 70
nM; passages 6 and 7: 80 nM; passages 8 and 9: 100 nM; and
passage 10: 120 nM). The ritonavir concentration was raised
from 60 nM (IC50 of HXB2) to ﬁnally 960 nM (passage 1: 60
nM; passage 2: 120 nM; passage 3: 240 nM; passages 4 and 5:
480 nM; and passage 6: 960 nm). HIV-1 RNA from the virus
supernatant of the passage with the highest drug concen-
tration was used for genotypic analysis of the complete viral
genome.
Drug susceptibility analysis. The infectious virus titre
(TCID50) was determined using endpoint dilutions in MT2
cells. Drug susceptibility of the viruses was determined in
duplicate using the multiple-cycle MTT assay [24]. In
addition, drug susceptibility was determined using a single-
cycle assay by Monogram Biosciences (http://www.
monogrambio.com) using the PhenoSense assay [25].
Viral RNA Analysis
Amplication and sequencing of the viral genome. Viral
RNA was isolated using the Nuclisens Isolation Kit (Organon
Teknika, http://www.biomerieux-usa.com). Brieﬂy, a 100 ll
sample was mixed with 900 ll lysis buffer and 50 ll silica and
incubated for 10 min at room temperature to allow binding
of the nucleic acid to the silica particles. Unbound material
was removed by several washing steps, after which the RNA
was eluted in 100 ll of 40 ng/ll polyA RNA.
The extracted HIV-1 RNA was then used to reverse
transcribe and amplify the viral genome, essentially as
described before [13] (Table S1). All PCR-ampliﬁed products
were puriﬁed using the QIAquick PCR puriﬁcation kit
(Qiagen, http://www.qiagen.com).
Subsequently, population sequencing was performed using
the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, http://www.appliedbiosystems.com) (Table S1).
Generation of Recombinant Virus
The viral DNA fragment including the C-terminal portion
of Gag (p2-NC-p1-p6) and protease was cloned into a HXB2
reference strain as previously described [26]. As a conse-
quence, the recombinant virus also acquired the wild-type
protease sequence from the in vitro selection experiment.
Therefore, the PCR product encompassing the C-terminal
portion of Gag and protease and the vector (pHXB2DCSPR)
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(pHXB2DCSPR) were ligated using the Rapid DNA Ligation
Kit (Roche Diagnostics http://www.roche-diagnostics.com).
Subsequently, the isolated plasmid was used to transfect
293T cells. Therefore, 5–6 3 10
6 293T cells were seeded the
day prior to transfection to achieve 90%–95% conﬂuence on
the day of transfection. For transfection of 10 lg of plasmid
DNA, Lipofectamine 2000 (Invitrogen, http://www.invitrogen.
com) was used according to the manufacturer’s protocol. The
transfection recombinant virus was harvested 2 d later.
Sequence analysis conﬁrmed the generation of a recombi-
nant HIV Gag clone of IVS-1 containing the K436EþI437T
amino acid substitution. In the original virus population of
IVS-1, a mixture at amino acid R464R/K in p6
gag was present,
and a virus clone containing the wild-type codon at position
464 was picked. The recombinant HIV Gag clone of IVS-32
contained the I437V amino acid change. The recombinant
HIV Gag clone of IVS-34 contained the I437T and an A15T
change in p6
pol. Since the IVS-34 virus stock contained the
K43T amino acid change in the viral protease, a virus stock
from an earlier passage was used for the generation of this
particular clone.
Viral Frameshift Analysis
Dual-luciferase constructs. A dual-luciferase reporter plas-
mid was used as described in Dulude et al. [27], based on
previously published systems [28,29]. In short, the HIV-1
frameshift region (nucleotides 2062 to 2139 of the HXB2
genome) was inserted between the coding sequence of the
Renilla luciferase and the ﬁreﬂy luciferase gene in an
appropriate vector derived from pcDNA3.1. In this pDual-
HIV( 1) construct, only the ribosomes that initiate translation
at the initiator codon for the Renilla luciferase but change the
reading frame by one base in the 59 direction in the frameshift
region synthesize the ﬁreﬂy luciferase, which is thus fused to
Renilla luciferase. A control plasmid, pDual-HIV(0), was used
to measure the translation level of an in-frame ﬁreﬂy
luciferase coding sequence relative to that of the Renilla
luciferase. Derivatives mutated in the frameshift region were
generated by PCR ampliﬁcation of the parental pDual-
HIV( 1) construct with the following forward and reverse
mutagenic primers: 59-CAGGGGGTACCGGATTGTACTGA-
GAGACAGGCTAATTTTTTAGGGN1AGN2N3CTGGCC-39
and 59-CCACTTGTAGAGCATGCGCCTTA-39, which con-
tains a KpnI and a Pﬂ23II restriction site (underlined),
respectively. Nucleotides at positions N1 ¼ A, N2 ¼ A, and N3
¼T in the wild-type HXB2 sequence were changed to N1¼G
and N3¼C inmutant IVS-1, N2¼G in mutant IVS-32, and N3¼
C in mutant IVS-34. The digested PCR products were then
inserted between the KpnI and Pﬂ23II restriction sites of the
wild-type pDual-HIV( 1) digested with the same enzymes.
Frameshift assays. The effect of the mutations in the HIV-1
frameshift region on the  1f r a m e s h i f te f ﬁ c i e n c yw a s
measured using the dual-luciferase reporter plasmids de-
scribed above. Frameshifting was monitored by transient
transfection into 293FT cells of the dual-luciferase vectors
(Invitrogen). The day before transfection, 2 3 10
4 cells/well
were seeded in 24-well plates and maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM, Gibco) supplemented with
10% fetal bovine serum (FBS, Wisent). Brieﬂy, 0.5 lg of each
dual-luciferase reporter construct was transfected into cells
using a standard calcium-phosphate precipitation method
[30], and cells were grown for 48 h before being harvested.
Cells were washed twice with PBS and lysed with 100 ll of the
Cell Passive Lysis Buffer (Promega, http://www.promega.com).
The ﬁreﬂy versus the Renilla luciferase activities of each
construct were measured as relative light units with a
Berthold Lumat LB 9507 luminometer (http://www.berthold-
tech.com), using a Dual-Luciferase Reporter Assay System kit
from Promega. Frameshift efﬁciencies were determined by
dividing the ratio of the ﬁreﬂy to Renilla luciferase activities
from the wild-type or mutant constructs to the ﬁreﬂy to
Renilla luciferase ratio from the in-frame pDual-HIV(0)
control construct.
Western Blot Analysis
Transfection. 293T cells were transfected with recombinant
proviral plasmids by the calcium-phosphate method, and PI
was added at the time of transfection where indicated.
Culture medium and cells were harvested after 48 h, and virus
particles were collected from cleared media by centrifugation
at 44,000 rpm in a TLA 45 Rotor (Beckman Coulter, http://
www.beckmancoulter.com) for 1 h at 4 8C.
Western blotting. For Western blot analysis, samples were
boiled in SDS sample buffer, separated by 12.5% or 15%
SDS-PAGE, and transferred to a nitrocellulose membrane.
Protein detection was performed following incubation with
antibodies against reverse transcriptase (RT), capsid (CA), or
nucleocapsid (NC) and appropriate secondary antibodies
using the Super Signal West detection kit (Pierce, http://www.
piercenet.com) according to the manufacturer’s protocol.
Quantitative Western blots were performed using the
Odyssey Infrared Imaging System as recommended by the
manufacturer (LI-COR, http://www.licor.com).
Analysis of RT Activity
Virus supernatant from 293T cells transfected with wild-
type HXB2 or 436Eþ437T constructs was used for the
detection of RT activity using the colorimetric Reverse
Transcriptase Assay (Roche Diagnostics) according to the
manufacturer’s protocol.
Peptide Cleavage Analysis
Peptide cleavage experiments were performed in triplicate
at pH 5.5, 37 8C, using 750 nM of wild-type protease and 200
lM substrate, and were analyzed on an HPLC Symmetry C18
column using a gradient of methanol in water. The reactions
were stopped after 1 h by adding triﬂuoroacetic acid (TFA) to
a ﬁnal concentration of 2%.
Database Analysis
The prevalence and drug susceptibility of the 431, 436, and
437 mutations in clinical samples was determined among
clinical samples submitted to Monogram Biosciences (for-
merly ViroLogic, Inc.) for routine combination phenotype/
genotype testing using PhenoSense HIV and GeneSeq HIV
[31]. These assays include ampliﬁcation by RT-PCR of the C-
terminal 82 amino acids of Gag as well as protease and RT
from the patient viruses. Phenotypic drug susceptibility (fold
change in IC50) of these recombinant viruses for the PIs
amprenavir, indinavir, nelﬁnavir, ritonavir, saquinavir, lopi-
navir, and atazanavir was determined. Nucleotide sequences
were determined by di-deoxy chain terminator sequencing.
All samples for which unambiguous Gag sequence could be
determined were included in the analysis. Mixtures contain-
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Primary protease resistance-associated mutations were de-
ﬁned as any change versus wild-type at positions 23, 24, 30, 32,
46, 47, 48, 50, 54, 82, 84, 88, and 90 in the viral protease, with
the following exceptions: I54V and N88D (not reported to
occur without other primary mutations) and V82I (known
polymorphism in PI-naive patients).
Investigation of the Association between Gag
Substitutions and Virological Response in the NARVAL
Trial
Baseline specimens from 203 highly active antiretroviral
therapy–experienced participants in the NARVAL trial
(ANRS 088) were sequenced with regard to the HIV protease
and C-terminal part of Gag [32]. Virological response
(deﬁned as mean change in viral load between entry and
week 12 of the treatment) were compared according to the
presence or absence of mutations at codons 431, 436, and 437
of HIV Gag by using the nonparametric Mann-Whitney or
Kruskall-Wallis test (p , 0.05 was considered to indicate
statistical signiﬁcance) in univariate analyses. Mutations for
which the p value was lower than 0.05 were retained and then
analyzed in a linear multivariate regression in order to assess
whether or not it was an independent predictor of the
virological response (mean change from baseline in viral
load). The independent variables used in the model were the
variables predictive of response in the overall multivariate
analysis of the NARVAL trial [33], that is to say prescription
of efavirenz in non-nucleoside reverse transcriptase inhib-
itor–naive patients, baseline prescription of lamivudine
(3TC), baseline prescription of abacavir (ABC) in ABC-naive
patients, baseline viral load, previous PI exposure for more
than 30 mo, number of nucleoside-associated mutations  3,
and randomization arm (SOC versus P). In addition, the
model was also adjusted on use of nelﬁnavir at baseline and
on the number of PI mutations (L10IRVF, K20RM, M36I,
A71VT, G73SA, V82AFTS, L90M) found to be associated with
the virological response in univariate analyses in this subset
of patients. Calculations were performed with the SPSS
software package (SPSS, http://www.spss.com).
Results
In Vitro Selection of HIV Variants Resistant to the PI
RO033-4649
The novel PI RO033-4649 with a high genetic barrier was
used to investigate the potential of alternative drug resistance
pathways in vitro [20]. This substrate-based inhibitor has an
Figure 1. Determination of Phenotypic Drug Susceptibility of the In Vitro-Selected Virus Populations
(A) Investigation of phenotypic drug susceptibility of IVS-1 (open squares) as compared to wild-type HIV (HXB2; filled squares) to the protease inhibitors
RO033-4649, lopinavir, tipranavir, atazanavir, and amprenavir. Fold increases in IC50 are indicated.
(B) Representation of the fold increases in phenotypic drug resistance of IVS-1, IVS-32, and IVS-34 as compared to wild-type HIV (HXB2) to the PI R0033–
4649, lopinavir (LPV), tipranavir (TPV), atazanavir (ATV), and amprenavir (AMP), and as a control to the RT inhibitor nevirapine (NVP).
doi:10.1371/journal.pmed.0040036.g001
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selection experiments (n ¼ 36) using an HIV-1 reference
strain (HXB2) were performed in the presence of very slowly
increasing concentrations of the PI. Only three individual
selection experiments out of 36 (IVS-1, IVS-32, and IVS-34)
resulted in viral populations that were able to replicate in the
presence of high concentrations of RO033-4649 ( 100 nM),
indicating that the novel PI exerted a strong selective
pressure. Phenotypic tests were performed to investigate
the resistance proﬁles of these viruses. Virus IVS-1 demon-
strated a 5.3-fold increase in IC50 for RO033-4649 (Figure 1A
and 1B), whereas the two other viruses demonstrated a 2- to
3-fold increase in IC50 (Figure 1B). Moreover, comparable and
even higher levels of resistance (up to 8-fold) were observed
for four clinically used PIs, lopinavir, tipranavir, atazanavir,
and amprenavir (Figure 1A and 1B). In a control assay no
change in susceptibility to a non-nucleoside RT inhibitor
(nevirapine) was observed (Figure 1B).
Determination of Genetic Correlates of Protease
Resistance
To identify the genotypic changes associated with PI
resistance, we sequenced the protease-coding region of all
three viruses. No amino acid changes in the viral protease
sequence were observed, with the exception of a single K43T
change in IVS-34. This substitution, when introduced into a
wild-type reference strain, did not cause an increase in
resistance to RO033-4649 (IC50 of 27 nM for both wild-type
and the K43T mutant).
The observation that PI resistance did not map to the
protease-coding region suggested that mutations in alter-
native regions were responsible for the observed phenotype.
Figure 2. Schematic Representation of the Distribution of all Amino Acid Changes Appearing during in vitro Selection Experiments Using RO033-4649
Horizontal bars below the gene organization scheme represent the genomes of viruses from the three in vitro selection experiments: IVS-1, IVS-32, and
IVS-34. Vertical lines illustrate the observed amino acid changes. The C-terminal portion of Gag was expanded to precisely map the nucleotide changes
leading to amino acid changes (bold) in both translational reading frames (Gag and GagPol). In addition, the three different cleavage sites (NC/p1, NC/
TFP, and TFP/p6
pol) are indicated. The control experiments, in which no drug was added during the in vitro selections, demonstrated no amino acid
changes in the viral Gag and protease region.
doi:10.1371/journal.pmed.0040036.g002
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three viruses was sequenced (Figure 2). Mutations unique to
each viral population were scattered throughout the three
genomes. Interestingly, all three viruses contained mutations
in the C-terminal region of the viral gag gene at amino acid
position 437 in the p1-coding region of gag (I437T/V). In IVS-
1 there was an adjacent K436E amino acid change. Two of the
viruses demonstrated selection of amino acid changes in the
overlapping reading frame (p6
pol) as well.
To determine whether the changes in gag alone could cause
the reduced susceptibility to PI, we cloned the C-terminal
portion of gag (p2-NC-p1-p6) and protease into the reference
strain HXB2. This resulted in the generation of three clones
containing the following changes compared to wild-type
HXB2: IVS-1 (436Eþ437T), IVS-32 (437V), and IVS-34 (437T
and A15T in p6
pol). Resistance proﬁles for these recombinant
viruses conﬁrmed that the genotypic changes observed in Gag
caused part of the initially observed reduced PI susceptibility.
This was most obvious for the combination of 436Eþ437T
(IVS-1), which displayed a 2- to 5-fold increase in IC50 to all
PIs in a multiple-cycle drug resistance analysis and a 2- to 3-
fold increase in a single-cycle assay (Figure 3). The single
substitutions caused an up to 2-fold increase in IC50 in the
single-cycle assay.
Identification of the Underlying Resistance Mechanism
The observed resistance to various PIs could be caused by
two different mechanisms. First, since the mutations are
located in the region that regulates Gag–GagPol ribosomal
frameshifting, the ratio of Gag to GagPol proteins in infected
cells could be altered in favor to increased levels of protease.
Second, since the amino acid changes are located near three
cleavage sites (NC/p1, NC/TFP, and TFP/p6pol), the poly-
protein processing rates could be altered.
Several approaches were used to investigate whether an
increase in the efﬁciency of frameshifting, resulting in
increased levels of HIV protease, could explain the resistant
phenotype (Figure 4). Inspection of the positions of the
mutations with respect to the viral frameshifting signal
suggested that such a mechanism would be unlikely (Figure
4). Experimentally, the effect of the observed mutations was
evaluated in a frameshift efﬁcacy assay using two reporter
genes, such that expression of the second reporter depends
on ribosomal frameshifting. The measured frameshift efﬁ-
ciencies for the p1 mutant constructs were not signiﬁcantly
different from those observed for the wild-type construct
(HXB2, 8.55% 6 0.84%; 436Eþ437T, 7.7% 6 0.42%; 437V,
7.94% 6 0.96%; and 437T, 9.68% 6 1.11%; Figure 4A). An
increase in frameshifting would result in increased levels of
all Pol proteins, including RT. We therefore investigated the
amount of viral RT in HXB2 as compared to the p1 mutant
436Eþ437T by Western blot analysis (Figure 4B). In line with
the frameshift assay results, no sign of increased RT levels was
observed; this was conﬁrmed by analysis the levels of RT
activity (normalized based upon levels of p24 [436Eþ437T,
104% RT activity relative to HXB2]). In conclusion, all data
showed that the PI resistance phenotype was not caused by
increased frameshift efﬁcacy.
The C-terminal Gag region contains three protease
cleavage sites (NC/p1, NC/TFP, and TFP/p6pol). To determine
whether altered cleavage could explain the observed pheno-
type, we investigated the overall proteolytic processing and
speciﬁcally the processing of the C-terminal part of Gag.
Since the 436 and 437 mutations are located distantly from
the actual cleavage site we decided to concentrate on cleavage
of the complete Gag polyprotein rather than analysis of
mutant decapeptides. To this end, 293T cells were transfected
with either a wild-type HXB2 proviral clone or the
436Eþ437T mutant construct in the presence or absence of
RO033-4649. Cell and particle lysates were analyzed by
Figure 3. Determination of Phenotypic Drug Susceptibility of C-Terminal Gag Clones
Representation of the fold increases in phenotypic drug susceptibility of the C-terminal Gag clone derived from IVS-1, containing the 436Eþ437T amino
acid change as compared to wild-type HIV (HXB2). The black bars indicate the fold increase as determined in the multiple-cycle MTT drug susceptibility
assay, and the gray bars indicate the fold increase as determined in the single-cycle PhenoSense drug susceptibility assay. Drug susceptibility to the PI
RO033-4649, LPV, TPV, ATV, AMP, ritonavir (RTV), saquinavir (SQV), indinavir (IDV), and nelfinavir (NFV), and as a control to the RT inhibitor NVP was
determined. RO033-4649 and TPV were not available at the time of PhenoSense assay testing.
doi:10.1371/journal.pmed.0040036.g003
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Table 1, and Figure S1). No major difference in overall
processing was observed. Speciﬁc antiserum against NC
showed that the fully cleaved NC was detected as the main
product for wild-type and mutant virus–infected cells and
virion preparations with a shift to the uncleaved precursor at
increasing PI concentrations (Figure 5). A notable difference
was observed, however, for the intermediate-processing
product NCp6 (containing the NC, p1, and p6 regions). In
mutant transfected cells, this product was more prominent
than in wild-type transfected cells, while the opposite was
observed for virion preparations (Figure 5). NCp6 was almost
undetectable in virus preparations from mutant 436Eþ437T–
infected cells, while it was clearly detectable in wild-type virus
(Figure 5; compare lanes 7 and 10). This difference became
much more obvious at a concentration of 50 nM RO033-4649
(Figure 5; compare lanes 8 and 11), where a difference in PI
sensitivity is actually observed (IC50 for wild type, 22 nM; for
IVS-1, 53 nM). This effect was observed for virus from four
independent transfections and was not due to loading
differences since the amounts loaded were normalized by
ELISA and quantitative immunoblot. Thus, the NCp6
intermediate was processed more efﬁciently in maturing
viruses of the resistant variant with mutations close to the
NC/p1 cleavage site.
Besides this effect on cleavage at the site close to the actual
mutation, we also observed an effect of the 436Eþ437T
mutation on polyprotein processing at a distant site.
Immunoblot analysis of wild-type and mutant transfected
cells and virus preparations using anti-CA antiserum again
revealed no obvious difference in processing patterns (Figure
S1). A clear difference was observed, however, when the
relative amount of fully processed CA compared to all CA-
reactive products in virion preparations at suboptimal
inhibitor concentration was compared by quantitative West-
ern blot analysis (Table 1). Complete processing of CA,
including late cleavage of the C-terminally adjacent p2
peptide is essential for CA condensation and viral infectivity
[34]. Without an inhibitor, .95% of all CA-reactive antigen
was completely processed, both in the case of wild-type and
resistance variant, and this ratio changed to ,0.1% at the
fully inhibitory concentration of 500 nM RO033-4649. At a
concentration of 50 nM, on the other hand, 20%–30% of CA
was completely processed in the case of the wild-type, while
35%–50% was completely processed in the case of the
resistance variant; this difference was again reproducible in
several independent experiments. The observed effect was
due mostly to a shift from fully processed CA to CA-p2 in the
case of wild-type virus (unpublished data). These results
indicated that amino acid changes near the NC/p1 cleavage
site enhanced not only the processing of the NC-p6
intermediate product but also overall polyprotein processing
and thus virus maturation. This effect was most pronounced
at a discriminating PI concentration.
In Vitro Selection Using Ritonavir
To investigate whether selection of genetic alterations close
to the protease cleavage sites is a general strategy used by the
virus to acquire PI resistance, we performed in vitro selection
experiments using the approved PI ritonavir. Multiple
selections (n ¼ 7) using an HIV-1 reference strain (HXB2)
were performed in the presence of increasing concentrations
of ritonavir. In all experiments we readily obtained viruses
containing known PI resistance–associated mutations in the
Figure 4. Schematic Representation of the Viral Frameshift Region and Investigation of Frameshift Efficiency
The RNA structure of the frameshift stimulatory signal is represented here [30,51]. The nucleotide and amino acid changes (between brackets) as
observed in our in vitro selection experiments are indicated.
(A) The relative frameshift efficiency of wild-type HIV (HXB2) and the p1 constructs of IVS-1 (436Eþ437T), IVS-32 (437V), and IVS-34 (437T). The values of
the frameshift efficiency are the means of four independent experiments, with bars representing the standard errors.
(B) Analysis of differences in levels of HIV GagPol products (RT, p66, and p51) as compared to HIV Gag products (CA, p24) by Western blot analysis.
doi:10.1371/journal.pmed.0040036.g004
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A431V amino acid substitution in the NC/p1 cleavage site,
combined with known resistance substitutions in protease
(V32I, M46I/L, I54V, V82A/F, and I84V). When we analyzed
clonal isolates it was found that this cleavage site change
occurred without changes in the protease itself in one
experiment. This A431V change, when introduced into a
wild-type reference strain, conferred 3.8-fold reduced sus-
ceptibility to ritonavir (IC50 of 7.3 nM [wild-type] as
compared to 28 nM [A431V mutant]). This observation
suggested that changes at other positions in the NC/p1
cleavage site could also directly cause PI resistance. To test
whether the PI resistance conferred by A431V was associated
with a change in processing efﬁciency at this site, we
investigated the relative turnover by wild-type protease of a
decapeptide corresponding to either the wild-type HXB2 NC/
p1 (ERQAN/FLGKI) or the mutant NC/p1 (ERQVN/FLGKI)
cleavage site sequence. We observed an increased rate of
peptide cleavage for the NC/p1 peptide containing the
ritonavir resistance–associated A431V substitution (relative
turnover of 0.18 [wild-type] as compared to 0.35 [for the
mutant]; Table 2).
Potential Clinical Significance of the Novel Drug
Resistance Mechanism
To investigate the potential clinical signiﬁcance of im-
proved cleavage associated with mutations at positions 431,
436, or 437 in HIV Gag, we performed two studies. First, we
determined the frequency at which these mutations were
found in clinical samples in a database of 28,241 patient
samples for which the genotype encompassing the protease,
the RT, and the C-terminal 82 amino acids of Gag and the
phenotypic measure of drug susceptibility were available. At
positions 431, 436, or 437, 13%, 8%, and 10% of the samples
had evidence of a mutation, respectively. In samples with no
primary PI mutations versus those with one or more such
mutations, the percentage of samples with any mutation at
positions 431, 436, and 437 was 1% versus 34%, 6% versus
12%, and 6% versus 16%, respectively. Multiple amino acid
substitutions were observed at 431 (mostly V and I), 436
(mostly R and G), and 437 (mostly V or L). These changes were
observed in viruses from infected patients and are associated
with previously ‘‘unexplained’’ PI resistance [31].
Second, we analyzed whether mutations at positions 431,
436, or 437 are associated with virological failure after PI
therapy. This was investigated for the NARVAL trial (ANRS
088) [35], a randomized study designed to assess the clinical
utility of drug-resistance testing as the basis for choosing a
new antiretroviral regimen following highly active antiretro-
viral therapy failure. We examined the prevalence of
substitutions at codons 431, 436, or 437 at baseline (after PI
therapy failure) and their association with week-12 virologic
response (deﬁned as the mean change in viral load) during
subsequent PI containing therapy (Table 3).
This analysis demonstrated a 37% prevalence of the A431V
substitution at baseline, which was not associated with lack of
virological response during subsequent PI therapy. The I437V
substitution, in contrast, which was prevalent in 5% of all
baseline isolates, was signiﬁcantly associated with lack of
virological response (p¼0.018 in univariate analysis; p¼0.031
in multivariate analysis). Changes at codon 436 (K436R/N)
were present in only a few patient isolates and could not be
evaluated. Of the clinical samples demonstrating a I437V
substitution, 60% also presented a primary protease muta-
tion at position 82 (p ¼ 0.020), which indicates that this
particular Gag mutation is also associated with a reduced
virological response when present in combination with
mutations in protease itself.
Discussion
In this study, we show that increased polyprotein process-
ing due to mutations in the natural substrate rather than the
enzyme itself represents a novel mechanism by which HIV-1
develops resistance to PIs.
To prevent the widespread development of HIV PI
resistance, novel approaches have been developed. These
approaches have in common that multiple amino acid
Figure 5. Analysis of Gag Polyprotein Processing
Western blot analysis of cell lysates (left panel) or virus particles (right panel) obtained by ultracentrifugation of cell culture supernatants from 293T cells
transfected with the respective recombinant virus plasmids in the absence of inhibitor or in the presence of 50 or 500 nM of RO033-4649. Molecular
mass standards are depicted on the left, Gag-derived proteins are identified on the right. Protein detection was performed following incubation witha
specific antibody against NC.
doi:10.1371/journal.pmed.0040036.g005
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clinical resistance. We demonstrate that HIV can escape this
strategy by selection of amino acid changes near the NC/p1
cleavage site, resulting in increased cleavage and PI resistance
in the absence of any protease mutation. Moreover, selection
experiments using an approved PI demonstrated that
enhanced processing at this site is a common principle in
resistance to PI. Furthermore, we demonstrate that this novel
mechanism is not only an in vitro observation, but may have
clinical relevance. First, the same mutations that confer in
vitro increased NC/p1 cleavage were also observed in vivo.
Moreover, in clinical samples lacking primary protease
mutations, both the 431V and the 437V mutation were
signiﬁcantly associated with a more than 5-fold increase in
resistance to at least one clinically used PI [31]. This suggests
that these changes at the NC/p1 cleavage site can affect
susceptibility to PIs independently from recognized muta-
tions in PR. Second, we show that enhanced processing of the
NC/p1 cleavage site is associated with virological failure
during PI therapy.
Development of PI resistance is believed to be due to a
stepwise accumulation of amino acid changes in the target
protein of the drug, the viral protease [5–7]. These mutations
are located in the substrate-binding pocket or at more distant
sites in the enzyme and directly or indirectly reduce the
afﬁnity of protease for the inhibitor, but also affect binding
of its natural substrate. Mutations close to the cleavage sites
in the viral Gag and GagPol proteins were considered to be
compensatory changes that restore binding of the mutant
enzyme and thus viral ﬁtness [14–17].
Previous studies have identiﬁed an association between the
selection of protease mutations and the appearance of
mutations in cleavage sites [36–38]. Changes at the p1/p6
cleavage site (L449F or P453L), which on their own do not
confer resistance, were associated with reduced sensitivity in
the background of the I50V in protease [18,39]. In this study,
we demonstrate the selection of substitutions in the Gag
substrate without any preceding alterations in the viral PR
sequence itself. These cleavage site changes on their own
contribute directly to PI resistance by increasing the
processing efﬁciency of the substrate.
HIV Gag processing is highly regulated and results in the
ordered generation of mature viral proteins [34,40–42].
Processing of the NC/p1 cleavage site is considered to be
among the slowest events, which may be determined by its
unusual amino acid sequence as compared to other HIV
cleavage sites. Site-directed mutagenesis has demonstrated
that particular changes at the P1 position of this cleavage site
accelerated the rate of processing [43]. Apparently, the rate of
cleavage is regulated by the use of suboptimal amino acids in
the cleavage sites and can be signiﬁcantly enhanced. The in
vitro experiments that we have performed demonstrated the
selection of NC/p1 cleavage site substitutions (A431V at the
P2 position, and the K436E and I437V/T at the more distant
P49 and P59 positions, respectively). We have shown that all
these amino acid changes are directly associated with
enhanced polyprotein processing. Western blot analysis
demonstrated not only increased processing of the inter-
mediate NC/p6 product but also enhanced overall polypro-
tein processing. Apparently, changing the kinetics of one of
the rate-limiting steps (NC/p1) impacts cleavage at the other
sites. Preliminary data indicate that the replicative capacity of
the 436Eþ437T cleavage site variant is severely reduced as
compared to wild-type HIV-1, indicating that enhanced Gag
cleavage may come at a price. Further research is warranted
to investigate the particular role of the individual cleavages
and their interaction.
Little is known regarding the exact role of the distant P49
and P59 positions in the actual cleavage process. They are not
positioned in the substrate-binding pocket of the enzyme,
and it is most likely that the increased processing we observed
is caused by structural changes in the Gag polyprotein,
altering the conformation of the substrate region. The A431V
substitution observed in our in vitro selection experiments
has been described before, both in vitro and in vivo [14–
16,18,36,38,44]. This mutation affects the P2 position of the
cleavage site and thus is in direct contact with the enzyme’s
substrate-binding pocket. We and others demonstrated that
changing the alanine to a valine, which is more common at
this P2 position in other cleavage sites, results in enhanced
cleavage at NC/p1 by wild-type protease (this study; [45]). This
Table 2. Relative Turnover of Wild-Type and Mutant NC/p1
Decapeptides by Wild-Type Protease
NC/p1 NC/p1 Decapeptide Sequence Relative Turnover
Wild type ERQAN-FLGKI 0.18
Mutant (A431V) ERQVN-FLGKI 0.35
The relative turnover of wild-type NC/p1 (ERQAN-FLGKI) and A431V mutant (ERQVN-FGKI)
decapeptides by wild-type protease was determined by HPLC.
doi:10.1371/journal.pmed.0040036.t002
Table 1. Polyprotein Processing of HIV Wild-Type and Mutant Virus Using a Quantitative Immunoblot Analysis
Virus RO033-4649 (nM) Completely Processed CA Sum of CA-Reactive Products Ratio of Completely Processed/Sum
HXB2 — 14,775 15,614 95%
50 6,741 24,293 28%
500 4 15,586 0.03%
436Eþ437T — 20,205 20,819 97%
50 11,371 23,960 48%
500 13 18,594 0.07%
Numbers shown for CA-reactive proteins are arbitrary units, completely processed CA was identified by comigration with purified CA. Sum of CA-reactive products includes Pr55
gag, CA,
and intermediate cleavage products (mainly CA-p2, MA-CA-p2, and MA-CA-p2-NC).
doi:10.1371/journal.pmed.0040036.t001
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type protease can bind the wild-type NC/p1 cleavage site less
well than the A431V-mutated cleavage site [46]. Moreover,
increased processing was also demonstrated in the back-
ground of primary drug-resistance mutations in the protease
sequence at codons 46, 82, 84, and 90 [45].
A clinical trial using a boosted PI (lopinavir with ritonavir)
has demonstrated virological failure in 20% of antiretroviral
therapy–naive patients [23]. This failure could not be
attributed to the development of traditional phenotypic or
genotypic PI resistance. Although therapy compliance may be
partly responsible, further studies are warranted to inves-
tigate if increased cleavage could explain this observation. In
addition, there are a number of studies indicating that in the
case of boosted lopinavir there are unexplained failures in a
setting where noncompliance is practically ruled out as the
cause of failure. This has become most obvious in the kaletra
monotherapy studies presented at the XVI International
AIDS Conference in Toronto, Canada (August 2006) [47–49] .
In all of these studies a proportion of patients fail
virologically. Again, the viruses of most of these patients lack
mutations in the viral protease, suggesting that alternative
mutations may play a role.
The current introduction into clinical practice of other
boosted PI regimens (such as darunavir) may further increase
the selection of resistant HIV variants employing an alter-
native resistance mechanism. This is supported by the
observation that in vitro selection experiments using this
inhibitor demonstrated phenotypic resistance that could not
be explained by resistance mutations in the viral protease
sequence [21]. Moreover, recent data demonstrate that part
of the in vitro observed resistance could be explained by gag
mutations, including a cleavage site mutation at codon 437
[50].
Our ﬁndings may have direct implications for drug
development and the monitoring of patients on a PI-failing
regimen. When novel drugs are being developed, we suggest
that one should evaluate whether this alternative resistance
mechanism provides an alternative escape route for the virus.
When evaluating a patient failing a PI-containing regimen
using either a phenotypic or a genotypic approach, it is
important to include the region containing the changes we
observed, not only to identify resistant viruses with a wild-
type protease sequence, but also because such changes may
enhance resistance in the presence of well-known protease
mutations.
It remains to be determined in future clinical studies
whether and to what extent cleavage site mutations contrib-
ute to virological failure. We speculate that the frequency will
depend on the classical variables determining treatment
response, such as compliance, drug interaction, protease
levels, and virological factors such as genetic barrier and the
level of resistance associated with the various protease
resistance mutations.
In conclusion, we have identiﬁed a novel mechanism of PI
resistance involving increased polyprotein processing due to
primary mutations in the natural substrate; these mutations
were observed both in vitro and in vivo. Further studies are
required to determine to what extent cleavage site mutations
may explain virological failure during PI therapy.
Supporting Information
Figure S1. Analysis of Gag Polyprotein Processing
Western blot analysis of virus particles obtained by ultracentrifuga-
tion of cell culture supernatants from 293T cells transfected with the
respective recombinant virus plasmids (wild-type or 436Eþ437T) in
the absence of inhibitor or in the presence of 50, 100, 200, or 500 nM
of RO033-4649. Protein detection was performed following incuba-
tion with a speciﬁc antibody against CA.
Found at doi:10.1371/journal.pmed.0040036.sg001 (37 KB JPG).
Table S1. Nucleotide Sequence of Primers Used for Ampliﬁcation
and Sequencing of HIV-1
Found at doi:10.1371/journal.pmed.0040036.st001 (28 KB XLS).
Acknowledgments
We are grateful to B. Muller for help with Western blot experiments.
We want to thank the patients and their doctors for providing clinical
information and samples. Part of the manuscript was presented at the
XIII International HIV Drug Resistance Workshop Tenerife, Spain 8–
12 June 2004 and at XIV International HIV Drug Resistance
Workshop, Que ´bec City, Canada, 7–11 June 2005.
Author contributions. MN, SL, BG, IWG, and CABB designed the
study. MN, SL, PS, EC, MR, DdJ, CC, IWG, DD, JK, NP, HGK, and FBV
analyzed the data. MN, NMvM, SL, EC, BG, CC, GHS, DD, NC, LBG,
NP, HGK, FBV, and CBB contributed to writing the paper. MN,
NMvM, PS, DdJ, IWG, and FBV collected data or did experiments for
the study. SL designed and analyzed the clinical part of the study (i.e.,
impact of Gag cleavage site mutations on the virological response to
highly active antiretroviral therapy). This was investigated for the
NARVAL (ANRS 088) trial. FBV was the study leader. BG tested the
wild-type and mutant virus in an infectious context, with or without
inhibitor, and did the Western blot analysis. MR performed the
kinetic analyses of peptide cleavage by HIV protease. GHS provided
compound for and helpful discussions about this study. DD designed
and did the experiments for measuring the frameshift efficiency of
viral variants of this study along with LBG. NP performed analysis of
genotypic and phenotypic data relating to gag mutations in clinical
samples. HGK performed quantitative immunoblot experiments
shown in the paper together with his technician.
References
1. Wensing AMJ, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in
Europe: Implications for clinical management. J Infect Dis 192: 958–966.
Table 3. Association between Substitutions at Codons 437 and 431 and Virological Response
Baseline Gag Sequence Patients, n (%) Mean Change in Viral Load (log) p-Value (Univariate) p-Value (Multivariate)
I437 non V 193 (95)  1.063 6 1.251 0.018 0.031
I437V 10 (5)  0.214 6 0.973
A431 non V 128 (63)  1.040 6 1.320 0.921 ND
A431V 75 (37)  0.987 6 1.124
doi:10.1371/journal.pmed.0040036.t003
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e36 0161
Novel HIV Protease Resistance Mechanism2. Wensing AM, Boucher CA (2003) Worldwide transmission of drug-resistant
HIV. AIDS Rev 5: 140–155.
3. Pao D, Andrady U, Clarke J, Dean G, Drake S, et al. (2004) Long-term
persistence of primary genotypic resistance after HIV-1 seroconversion. J
Acquir Immune Deﬁc Syndr 37: 1570–1573.
4. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, et al. (2002)
Persistence and ﬁtness of multidrug-resistant human immunodeﬁciency
virus type 1 acquired in primary infection. J Virol 76: 1753–1761.
5. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, et al. (1994)
Selection of multiple human immunodeﬁciency virus type 1 variants that
encode viral proteases with decreased sensitivity to an inhibitor of the viral
protease. Proc Natl Acad Sci U S A 91: 5597–5601.
6. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, et al. (1995)
In vivo emergence of HIV-1 variants resistant to multiple protease
inhibitors. Nature 374: 569–571.
7. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, et al. (1996)
Ordered accumulation of mutations in HIV protease confers resistance to
ritonavir. Nat Med 2: 760–766.
8. Gulnik S, Suvorov LI, Liu B, Yu B, Anderson B, et al. (1995) Kinetic
characterization and cross-resistance patterns of HIV-1 protease mutants
selected under drug pressure. Biochem 34: 9282–9287.
9. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, et al. (1997)
Impaired ﬁtness of human immunodeﬁciency virus type 1 variants with
high-level resistance to protease inhibitors. J Virol 71: 1089–1096.
10. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, et al. (1999)
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
Eur J Biochem 263: 238–245.
11. Quinones-Mateu ME, Arts EJ (2001) HIV-1 ﬁtness: Implications for drug
resistance, disease progression and global epidemic evolution. In: Kuiken
C, Foley B, Hahn B, Marx PA, McCutchan F, et al., editors. HIV sequence
compendium.(2001) Los Alamos (New Mexico): Theoretical Biology and
Biophysics Group, Los Alamos National Laboratory. pp. 134–170.
12. Borman AM, Paulos S, Clavel F (1996) Resistance of human immunodeﬁ-
ciency virus type 1 to protease inhibitors: Selection of resistance mutations
in the presence and absence of the drug. J Gen Virol 77: 419–426.
13. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, et al. (1999)
Increased ﬁtness of drug resistant HIV-1 protease as a result of acquisition
of compensatory mutations during suboptimal therapy. AIDS 13: 2349–
2359.
14. Mammano F, Trouplin V, Zennou V, Clavel F (2000) Retracing the
evolutionary pathways of human immunodeﬁciency virus type 1 resistance
to protease inhibitors: Virus ﬁtness in the absence and in the presence of
drug. J Virol 74: 8524–8531.
15. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, et al. (1996) Second
locus involved in human immunodeﬁciency virus type 1 resistance to
protease inhibitors. J Virol 70: 3763–3769.
16. Zhang Y-M, Imamichi H, Imamichi T, Lane HC, Falloon J, et al. (1997) Drug
resistance during indinavir therapy is caused by mutations in the protease
gene and in its Gag substrate cleavage sites. J Virol 71: 6662–6670.
17. Mammano F, Petit C, Clavel F (1998) Resistance-associated loss of viral
ﬁtness in human immunodeﬁciency virus type 1: Phenotypic analysis of
protease and gag coevolution in protease inhibitor-treated patients. J Virol
72: 7632–7637.
18. Maguire MF, Guinea R, Grifﬁn P, et al. (2002) Changes in human
immunodeﬁciency virus type 1 Gag at positions L449 and P453 are linked
to I50V protease mutants in vivo and cause reduction of sensitivity to
amprenavir and improved viral ﬁtness in vitro. J Virol 76: 7398–7406.
19. Kempf DJ, Marsh KC, Kumar G, Macmanus S, Elston RC, et al. (1997)
Pharmacokinetic enhancement of inhibitors of the human immunodeﬁ-
ciency virus protease by coadministration with ritonavir. Antimicrob
Agents Chemother 41: 654–660.
20. Heilek-Snyder G, Kohli A, Cammack N, Parkin N (2003) In vitro cross
resistance proﬁle of RO033-4649 against a panel of multiply-substituted
protease inhibitor resistant viruses: Role of common protease resistance
mutations. Antiviral Therapy 8: S21.
21. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, et al. (2005)
TMC114, a novel human immunodeﬁciency virus type 1 protease inhibitor
active against protease inhibitor-resistant viruses, including a broad range
of clinical isolates. Antimicrob Agents Chemother 49: 2314–2321.
22. Gulnik SV, Afonina EI, Yu B, Eissenstat M, Guerassina, et al. (2004) Highly
potent HIV protease inhibitors with broad activity against multidrug
resistant strains. Antivir Ther 9S: 18.
23. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, et al. (2004)
Incidence of resistance in a double-blind study comparing lopinavir/
ritonavir plus stavudine and lamivudine to nelﬁnavir plus stavudine and
lamivudine. J Infect Dis 189: 51–60.
24. Boucher CAB, Keulen W, van Bommel T, Nijhuis M, de Jong D, et al. (1996)
Human immunodeﬁciency virus type 1 drug susceptibility determination
by using recombinant viruses generated from patient sera tested in a cell-
killing assay. Antim Ag Chemoth 40: 2404–2409.
25. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel
phenotypic drug susceptibility assay for HIV-1. Antim Ag Chemoth 44:
920–928.
26. van Maarseveen NM, Huigen MCDG, de Jong D, Smits AM, Boucher CA, et
al. (2006) A novel real-time PCR assay to determine relative replication
capacity for HIV-1 protease variants and/or reverse transcriptase variants. J
Virol Methods 133: 185–194.
27. Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N (2006)
Decreasing the frameshift efﬁciency translates into an equivalent reduction
of the replication of the human immunodeﬁciency virus type 1. Virology.
327: 127–136.
28. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF (1998) A dual-
luciferase reporter system for studying recoding signals. RNA 4: 479–486.
29. Harger JW, Dinman JD (2003) An in vivo dual-luciferase assay system for
studying translational recoding in the yeast Saccharomyces cerevisiae. RNA 9:
1019–1024.
30. Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells:
Optimization of critical parameters affecting calcium-phosphate precip-
itate formation. Nucleic Acids Res 24: 596–601.
31. Parkin N, Chappey C, Lam E, Petropoulos C (2005) Reduced susceptibility
to protease inhibitors in the absence of primary protease inhibitor
resistance-associated mutations. Antivir Ther 10: S118.
32. Lastere S, Dalban C, Collin G, Descamps D, Girard PM, et al. (2004) Impact
of insertions in the HIV-1 p6 PTAPP region on the virological response to
amprenavir. Antivir Ther 9: 221–227.
33. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, et al. (2003)
Predictors of the virological response to a change in the antiretroviral
treatment regimen in HIV-1-infected patients enrolled in a randomized
trial comparing genotyping, phenotyping and standard of care (Narval
trial, ANRS 088). Antivir Ther 8: 427–434.
34. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, et al. (1998)
Sequential steps in human immunodeﬁciency virus particle maturation
revealed by alterations of individual Gag polyprotein cleavage sites. J Virol
72: 2846–2854.
35. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002)
Phenotypic or genotypic resistance testing for choosing antiretroviral
therapy after treatment failure: a randomized trial. AIDS 16: 727–736.
36. Cote HC, Brumme ZL, Harrigan PR (2001) Human immunodeﬁciency virus
type 1 protease cleavage site mutations associated with protease inhibitor
cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol
75: 589–594.
37. Kaufmann GR, Suzuki K, Cunningham P, Mukaide M, Kondo M, et al. (2001)
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6
mutations on the virological response to quadruple therapy with
saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum
Retroviruses 17: 487–497.
38. Bally F, Martinez R, Peters S, Sudre P, Telenti A (2000) Polymorphism of
HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical signiﬁcance and
implications for resistance to protease inhibitors. AIDS Res Hum
Retroviruses 16: 1209–1213.
39. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, et al. (2002)
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and re-
duced replication capacity. AIDS 16: 1009–1017.
40. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, et al. (1994)
The p2 domain of human immunodeﬁciency virus type 1 Gag regulates
sequential proteolytic processing and is required to produce fully
infectious virions. J Virol 68: 8017–8027.
41. Swanstrom R, Wills J (1997) Retroviral gene expression: Synthesis,
processing, and assembly of viral proteins. In: Varmus HE, Cofﬁn J, Hughes
S, editors. Retroviruses. Cold Spring Harbor (N.Y.): Cold Spring Harbor
Laboratory Press. pp. 263–334.
42. Krausslich HG, Ingraham RH, Skoog MT, Wimmer E, Pallai PV, et al. (1989)
Activity of puriﬁed biosynthetic proteinase of human immunodeﬁciency
virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A
86: 807–811.
43. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R (2002) Replacement of
the P1 amino acid of human immunodeﬁciency virus type 1 Gag processing
sites can inhibit or enhance the rate of cleavage by the viral protease. J
Virol 76: 10226–10233.
44. Dauber DS, Ziermann R, Parkin N, Maly DJ, Mahrus S, et al. (2002) Altered
substrate speciﬁcity of drug-resistant human immunodeﬁciency virus type
1 protease. J Virol 76: 1359–1368.
45. Feher A, Weber IT, Bagossi P, Boross P, Mahalingam B, et al. (2002) Effect
of sequence polymorphism and drug resistance on two HIV-1 Gag
processing sites. Eur J Biochem 269: 4114–4120.
46. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA (2004) Structural
basis for coevolution of a human immunodeﬁciency virus type 1
nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral
protease. J Virol 78: 12446–12454.
47. Arribas J, Pulido F, Delgado R, Pan ˜o JR, Lorenzo A, et al. (2006) Lopinavir/
ritonavir as single-drug maintenance therapy in patients with HIV-1 viral
suppresion: 48 week results of a randomized, controlled, open label, clinical
trial (OKO4 study) [abstract WePe12.3C05]. The 3rd IAS Conference on
HIV Pathogenesis and Treatment; 2005 24–27 July; Rio de Janiero.
International AIDS Society. Available: http://www.iasociety.org. Accessed
12 December 2006.
48. Delfraissy JF, Flandre P, Delaugerre C, Horban A, Girard P-M, et al. (2006)
MONARK: 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy
compared to LPV/r þ zidovuidne/lamivudine in antiretroviral-naive
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e36 0162
Novel HIV Protease Resistance Mechanismpatients [abstract THLB0202].XVI International AIDS Conference;2006
13–18 August;Toronto. International AIDS Society.
49. Cameron W, da Silva B, Arribas J, Myers R, Bellos N, et al. (2006) A two-year
randomized controlled clinical trial in antiretroviral-naive subjects using
lopinavir/ritonavir monotherapy after initial induction treatment com-
pared to an efavirenz 3-drug regimen [abstract THLB0201].XVI Interna-
tional AIDS Conference;2006 13–18 August;Toronto. International AIDS
Society.
50. De Meyer S, Azijn H, Fransen E, De Baere I, van Ginderen M, et al. (2006)
The pathway leading to TMC114 resistance is different for TMC114
compared with other protease inhibitors. Antivir Ther 11: S24.
51. Dulude D, Baril M, Brakier-Gingras L (2002) Characterization of the
frameshift stimulatory signal controlling a programmed  1 ribosomal
frameshift in the human immunodeﬁciency virus type 1. Nucleic Acids Res
30: 5094–5102.
Editors’ Summary
Background. Twenty-five years ago, infection with the human
immunodeficiency virus (HIV)—the causative agent of AIDS—was a
death sentence. However, drugs that attack various stages of the HIV life
cycle were soon developed that, although not curing the infection, kept
it in check when used in combination and greatly increased the life
expectancy of people infected with HIV. Unfortunately, viruses resistant
to these drugs have rapidly emerged and antiviral therapy now fails in
many patients. The use of HIV protease inhibitors (PIs) in combination
therapies, for example, has led to the stepwise selection of viral variants
resistant to these drugs. Resistance is first acquired when the viral
protease changes so that PIs no longer bind to it and inhibit it efficiently.
These changes often reduce the efficiency with which the protease binds
its substrates—polyproteins called Gag and GagPol that it chops up into
smaller proteins to make new viral particles. So the next step is the
accumulation of changes elsewhere in the protease that make it work
better, and sometimes changes in its substrate that make it easier to cut;
these compensatory changes do not directly affect viral resistance to PIs.
Why Was This Study Done? To prevent viruses with resistance to PIs
emerging, drug doses are kept high in patients and new PIs are being
developed with high potency against known PI-resistant HIV variants.
Both approaches set a ‘‘high genetic barrier’’ to the development of PI
resistance by ensuring that HIV has to incorporate many changes in its
protease to become resistant. But, the HIV genome naturally changes—
mutates—very rapidly, so novel HIV variants could emerge that are less
susceptible to the new potent PIs without the virus having to leap this
high genetic barrier. In this study, the researchers have investigated
whether HIV can find an alternative route to PI resistance that does not
involve the introduction of multiple changes into its protease.
What Did the Researchers Do and Find? The researchers took wild-
type HIV and treated it in the laboratory with a new PI regimen that has a
high genetic barrier. By gradually increasing its concentration, the
researchers selected three viral populations that were able to grow in 4-
to 8-fold higher concentrations of the PI than wild-type virus. None of
these populations had mutations in the viral protease. Instead, they all
had mutations near one of the sites—the NC/p1 site—where the
protease normally cuts the Gag polyprotein. These mutations, the
researchers report, enhanced the overall efficiency with which the wild-
type protease cleaved the polyprotein, and a selection experiment with
another PI showed that the development of PI resistance through
alterations near the NC/p1 cleavage site was not unique to one PI. The
researchers also investigated the potential clinical significance of this
new drug resistance mechanism by looking for the same mutations in
nearly 30,000 patient samples. Many of the samples did indeed have
these mutations. Finally, they showed that mutations at the NC/p1
cleavage site were associated with virological failure (increased viral
replication) during PI therapy in an ongoing clinical trial.
What Do These Findings Mean? These results suggest that increased
polyprotein processing because of mutations in the natural substrate of
the HIV protease might be a new mechanism by which HIV can become
resistant to PIs. This strategy, which occurs in the laboratory and in
patients, allows HIV to develop PI resistance without the need for
multiple changes in its protease and so avoids the high genetic barrier to
resistance that new PIs provide. Clinical studies are now needed to test
which of the mutations seen in this study contribute to virological failure,
whether the degree of this failure is clinically relevant, and whether these
substrate mutations enhance the effect of protease mutations. If the
clinical importance of the new mechanism is confirmed, genetic
examination of both the polyprotein and the protease will be needed
when trying to figure out why a PI-containing therapy is failing in
individual patients. Furthermore, it will be necessary to test whether this
mechanism can contribute to the development of resistance when
evaluating new drugs.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040036.
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